A recent publication reports on new findings regarding the complex interaction between the sympathetic nervous system and the kidneys in the development of so-called salt-sensitive hypertension. The study demonstrated for the first time that alpha-1 adrenergic receptor blockers reduce the activity of the sodium reabsorption process in the kidneys, thereby increasing salt excretion and, in this way, lowering blood pressure.
This means that a targeted treatment for salt-sensitive hypertension could soon be available. This condition is a common reason why patients do not respond to conventional blood pressure-lowering drugs. Particularly feared complications include heart attacks and strokes, as well as kidney failure or blindness.
The well-known blood pressure-lowering effect of alpha-blockers lies in their vasodilatory action, which is achieved by relaxing the smooth muscle of the blood vessels. The study demonstrated for the first time that alpha-1 adrenoreceptor blockers also reduce the activity of the sodium reabsorption process and thereby lower blood pressure.The alpha-1 receptor blockers were effective both when administered before the onset of high salt intake and in cases of established salt-sensitive hypertension.
“The research findings demonstrate how complex the interrelationships between the sympathetic nervous system and the kidneys are in the development of hypertension,” comments Ulrich Wenzel of the University Medical Centre Hamburg-Eppendorf on the study: “If these findings from animal experiments are confirmed in clinical trials, this would be of great practical relevance.”
References:
Boston University School of Medicine
press release, High Blood Pressure League: https://www.hochdruckliga.de/pressemitteilung/neuer-therapieansatz-bei-salzsensitivem-bluthochdruck
Original: Regulation of the NCC (Sodium Chloride Cotransporter) in Dahl Salt-Sensitive Hypertension; Hypertension 2020 Nov; 76 (5): 1461–69; https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.15928